We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

What's that noise?

2 February 2006 By Robert Cyran

Investors always figured the UK drugmaker had several years of smooth sailing but 2006 earnings may be flat. And bigger rocks loom ahead. With a wave of patent expirations in 2008, the stock deserves more than its current 15% discount.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)